Pharmathen

Executive Summary

Pharmathen is a private, research-centered pharmaceutical company headquartered in the Netherlands, with operations in Athens, Greece. Founded in 1995, the company specializes in developing innovative generic drugs and offers a comprehensive package of integrated services, including finished products, know-how, and technological and regulatory support to its global partners. By focusing on high-value generics and complex formulations, Pharmathen has positioned itself as a key player in the generic pharmaceutical market, leveraging its R&D capabilities to bring cost-effective alternatives to patients worldwide. The company's private status allows it to operate with a long-term strategic vision, prioritizing product development and partnerships over short-term shareholder returns. With a strong emphasis on innovation and regulatory expertise, Pharmathen is well-equipped to navigate the competitive generic landscape. The company's integrated service model not only generates recurring revenue but also deepens relationships with partners in emerging and developed markets. Although financial details are not publicly disclosed, Pharmathen's sustained presence in the industry since 1995 suggests a stable business with a proven track record. However, as a private entity, it faces challenges such as limited access to capital markets and reliance on a relatively small portfolio. Overall, Pharmathen represents a solid but not high-growth opportunity in the generic drugs sector.

Upcoming Catalysts (preview)

• Q3 2026New ANDA approvals for complex generics60% success
• Q4 2026Expansion into new geographic markets through partnerships70% success
• TBDLaunch of first-to-file generic product40% success